Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2016, Article ID 3597609, 13 pages
http://dx.doi.org/10.1155/2016/3597609
Review Article

A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma

1Market Access and Outcomes Strategy, RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, Durham, NC 27709, USA
2US Health Outcomes, Oncology, GlaxoSmithKline, 5 Crescent Drive, Philadelphia, PA 19112, USA
3Epidemiology, RTI Health Solutions, 1440 Main Street, Suite 310, Waltham, MA 02451, USA
4US Medical Affairs, Oncology, GlaxoSmithKline, 5 Crescent Drive, Philadelphia, PA 19112, USA

Received 1 February 2016; Accepted 6 June 2016

Academic Editor: Antoine Italiano

Copyright © 2016 Ann Colosia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. National Cancer Institute, Adult Soft Tissue Sarcoma Treatment (PDQ®)—Health Professional Version, National Cancer Institute, Bethesda, Md, USA, 2016, http://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq.
  2. C. Fletcher, J. A. Bridge, P. Hogendoorn et al., World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Soft Tissue and Bone, IARC Press, Lyon, France, 2013.
  3. National Cancer Institute, Surveillance, Epidemiology, and End Results Program, SEER Stat Fact Sheets: Soft Tissue Including Heart Cancer, 2016, http://seer.cancer.gov/statfacts/html/soft.html.
  4. R. Wesolowski and G. T. Budd, “Use of chemotherapy for patients with bone and soft-tissue sarcomas,” Cleveland Clinic Journal of Medicine, vol. 77, supplement 1, pp. S23–S26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. National Comprehensive Cancer Network, “NCCN clinical practice guidelines in oncology (NCCN Guidelines®): soft tissue sarcoma,” Version 2, http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf.
  6. ESMO/European Sarcoma Network Working Group, “Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 23, supplement 7, pp. vii92–vii99, 2012. View at Publisher · View at Google Scholar
  7. R. Chugh, J. K. Wathen, R. G. Maki et al., “Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3148–3153, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. George, P. Merriam, R. G. Maki et al., “Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas,” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3154–3160, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. Votrient [package insert], GlaxoSmithKline (now Novartis), 2016, https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/votrient.pdf.
  10. European Medicines Agency, Yondelis European Public Assessment Report, 2015, http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000773/human_med_001165.jsp&mid=WC0b01ac058001d124.
  11. W. T. A. van der Graaf, J.-Y. Blay, S. P. Chawla et al., “Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial,” The Lancet, vol. 379, no. 9829, pp. 1879–1886, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. V. H. C. Bramwell, H. T. Mouridsen, A. Santoro et al., “Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas,” Cancer Chemotherapy and Pharmacology, vol. 18, supplement 2, pp. S13–S16, 1986. View at Publisher · View at Google Scholar · View at Scopus
  13. V. H. C. Bramwell, H. T. Mouridsen, A. Santoro et al., “Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas,” European Journal of Cancer and Clinical Oncology, vol. 23, no. 3, pp. 311–321, 1987. View at Publisher · View at Google Scholar · View at Scopus
  14. V. H. C. Bramwell, H. T. Mouridsen, A. Santoro et al., “Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group,” Cancer Chemotherapy and Pharmacology, vol. 31, supplement 2, pp. S180–S184, 1993. View at Google Scholar · View at Scopus
  15. G. D. Demetri, S. P. Chawla, M. von Mehren et al., “Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules,” Journal of Clinical Oncology, vol. 27, no. 25, pp. 4188–4196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. X. García-Del-Muro, A. López-Pousa, J. Maurel et al., “Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study,” Journal of Clinical Oncology, vol. 29, no. 18, pp. 2528–2533, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Pautier, A. Floquet, N. Penel et al., “Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a fédération nationale des centres de lutte contre le cancer (FNCLCC) french sarcoma group study (TAXOGEM study),” Oncologist, vol. 17, no. 9, pp. 1213–1220, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. ClinicalTrials.gov, NCT00753688, Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy (PALETTE), 2013, http://clinicaltrials.gov/ct2/show/NCT00753688?term=00753688&rank=1.
  19. A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration,” BMJ, vol. 339, Article ID b2700, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. National Institute for Health and Care Excellence, Guide to the Single Technology Appraisal Process, 2009, https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/Guide-to-the-single-technology-appraisal-process.pdf.
  21. Centre for Reviews and Dissemination, Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care, 2008, http://www.york.ac.uk/media/crd/Systematic_Reviews.pdf.
  22. D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” The British Medical Journal, vol. 339, no. 7716, Article ID b2535, pp. 332–336, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Bui-nguyen, I. Ray-coquard, C. Chevreau et al., “High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial,” Annals of Oncology, vol. 23, no. 3, pp. 777–784, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. R. G. Maki, J. K. Wathen, S. R. Patel et al., “Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2755–2763, 2007. View at Google Scholar
  25. L. Paz-Ares, A. López-Pousa, A. Poveda et al., “Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone,” Investigational New Drugs, vol. 30, no. 2, pp. 729–740, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. FDA Oncologic Drugs Advisory Committee, “Votrient® (pazopanib) tablets for treatment of patients with soft tissue sarcoma,” Briefing Document NDA 22-465, 2012, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM296303.pdf. View at Google Scholar
  27. GlaxoSmithKline, VEG110727. A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy. Results Summary, GlaxoSmithKline, Brentford, UK, 2014, http://www.gsk-clinicalstudyregister.com/study/VEG110727#rs.
  28. G. D. Demetri, M. von Mehren, R. L. Jones et al., “Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial,” Journal of Clinical Oncology, vol. 34, no. 8, pp. 786–793, 2016. View at Publisher · View at Google Scholar
  29. J. Martin-Broto, A. L. Pousa, R. de Las Penas et al., “Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: a Spanish Group for Research on Sarcoma study,” Journal of Clinical Oncology, vol. 34, no. 19, pp. 2294–2302, 2016. View at Publisher · View at Google Scholar
  30. Dacarbazine, Teva Pharmaceuticals, North Wales, Pa, USA, 2014, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=26e91082-7698-4680-beab-07c47802f0f9.
  31. Gemzar, Eli Lilly and Company, Indianapolis, Ind, USA, 2014, http://pi.lilly.com/us/gemzar.pdf.
  32. C. N. Sternberg, I. D. Davis, J. Mardiak et al., “Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial,” Journal of Clinical Oncology, vol. 28, no. 6, pp. 1061–1068, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Sharma, S. Takyar, S. C. Manson, S. Powell, and N. Penel, “Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review,” BMC Cancer, vol. 13, article 385, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Pacey, M. J. Ratain, K. T. Flaherty et al., “Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a phase II randomized discontinuation trial,” Investigational New Drugs, vol. 29, no. 3, pp. 481–488, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. A. T. van Oosterom, H. T. Mouridsen, O. S. Nielsen et al., “Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients,” European Journal of Cancer, vol. 38, no. 18, pp. 2397–2406, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. U. S. Food and Drug Administration News Release, FDA Approves First Drug to Show Survival Benefit in Liposarcoma, 2016, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm483714.htm.
  37. J.-Y. Blay, Z. Pápai, A. W. Tolcher et al., “Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial,” The Lancet Oncology, vol. 16, no. 5, pp. 531–540, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Schöffski, S. Chawla, R. G. Maki et al., “Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial,” The Lancet, vol. 387, no. 10028, pp. 1629–1637, 2016. View at Publisher · View at Google Scholar